Publications by authors named "Klaus Bosslet"

Claim this Profile
C
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Frieder Bauss, Martin Lechmann, Ben-Fillippo Krippendorff, Roland Staack, Frank Herting, Klaus Bosslet

Mol Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
Peter Brünker, Katharina Wartha, Thomas Friess, Sandra Grau-Richards, Inja Waldhauer, Klaus Bosslet

Mol Cancer Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet

Mol Cancer Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma.
Barbara-Ann Guinn, Klaus Bosslet, Cindy Lee, Deborah Richardson, Kim Orchard

Eur J Haematol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Jin Gao, Jon W Chesebrough, Susan A Cartlidge, Sally-Ann Ricketts, Leonard Incognito, Klaus Bosslet

Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.
G Siemeister, U Luecking, C Wagner, K Detjen, C Mc Coy, Klaus Bosslet

Biomed Pharmacother· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.
Thomas E Mürdter, Godehard Friedel, Janne T Backman, Monika McClellan, Monika Schick, Klaus Bosslet

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis